Since the discovery of the human immunodeficiency virus (HIV) in 1983, dramatic progress
has been made in the development of novel antiviral drugs. The HIV epidemic fuelled the …

The need for new classes of antiretroviral drugs has become apparent because of
increasing concern about the long-term toxic effects of existing drugs, the need to combat …

Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a
chronic and manageable disease. However, treatment is only effective until HIV-1 develops …

Infection of target cells by HIV is a complex, multi-stage process involving attachment to host
cells and CD4 binding, coreceptor binding, and membrane fusion. Drugs that block HIV …

Entry of HIV into target cells is a complex, multi-stage process involving sequential
attachment and CD4 binding, coreceptor binding, and membrane fusion. HIV entry inhibitors …

The genetic diversity of human immunodeficiency virus type 1 (HIV-1) results from a
combination of point mutations and genetic recombination, and rates of both processes are …

The HIV gp41 N-trimer pocket region is an ideal viral target because it is extracellular, highly
conserved, and essential for viral entry. Here, we report on the design of a pocket-specific d …

Peptides have great potential as therapeutic agents, but their use is often limited by
susceptibility to proteolysis and their resulting in vivo fragility. In this review, we focus on …

Entry inhibitors represent a new class of antiretroviral agents for the treatment of infection
with HIV-1. While resistance to other HIV drug classes has been well described, resistance …

O uso da terapia anti-retroviral combinada (TARV) aumentou a expectativa de vida dos
portadores do vírus da imunodeficiência humana (HIV) e, como conseqüência, torna-se …